Colorectal cancer is one of the leading causes of death in the United States, with an estimated 134,490 new cases and 49,190 deaths in 2020 alone.1 Early detection and treatment of colorectal cancer is essential to improving outcomes, and flexible sigmoidoscopy has been identified as a revolutionary way to detect colorectal cancer in its early stages. Flexible sigmoidoscopy is a safe, non-invasive procedure that provides an effective way to detect colorectal cancer in its earliest stages, when it is most treatable. In this article, we will explore the benefits of flexible sigmoidoscopy as a revolutionary way to detect colorectal cancer.
Flexible sigmoidoscopy is a procedure that uses a thin, flexible tube with a light and camera on the end to examine the inside of the lower part of the colon, or sigmoid colon. The procedure is performed by a doctor, and typically takes only a few minutes. During the procedure, the doctor will insert the tube into the rectum and move it around to examine the inside of the sigmoid colon. The doctor will be able to view any abnormalities or growths on the inside of the sigmoid colon, and can take a biopsy if needed.
Flexible sigmoidoscopy is a safe, non-invasive procedure that provides an effective way to detect colorectal cancer in its earliest stages, when it is most treatable. The procedure is relatively quick and easy to perform, and does not require any sedation. Additionally, the procedure is relatively inexpensive compared to other colorectal cancer screening methods. Flexible sigmoidoscopy is also beneficial because it can detect polyps, which are small growths in the lining of the colon that can become cancerous. Polyps can be removed during the procedure, which can help to prevent colorectal cancer from developing. Additionally, the procedure can detect colorectal cancer in its earliest stages, when it is most treatable.
Flexible sigmoidoscopy is recommended for people aged 50 and older, and those who are at an increased risk for colorectal cancer. People who are at an increased risk for colorectal cancer include those with a family history of the disease, those with inflammatory bowel disease, and those who have had previous polyps removed. Additionally, people with certain genetic conditions, such as Lynch syndrome, are at an increased risk for colorectal cancer and should consider getting a flexible sigmoidoscopy.
Flexible sigmoidoscopy is a revolutionary way to detect colorectal cancer in its earliest stages, when it is most treatable. The procedure is safe, non-invasive, and relatively inexpensive, and can detect polyps and other abnormalities in the lining of the sigmoid colon. Flexible sigmoidoscopy is recommended for people aged 50 and older, and those who are at an increased risk for colorectal cancer. Early detection and treatment of colorectal cancer is essential to improving outcomes, and flexible sigmoidoscopy can help to ensure that the disease is detected and treated in its earliest stages.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation